Adults 20 to 70, any sex, with Bone Loss, Alveolar. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Mesial-distal (M-D) Bone LossPrimary· Baseline, surgical visit 1 day, 4 months, 5 months, 12 months, 24 months
Comparing mesial-distal (M-D) bone loss between the two groups. This will be measured in millimeters using standardized radiographs of the implant site at the screening visit, surgical visit, 4 months post-op, 5 months post-op, 12 months post-op, and 24 months post-op visits.
The survival rate of the two groups will be recorded as a percentage at the 5 month post-op, 12 month post-op, and 24 month post-op visits based on clinician assessment.
5 months (loading)
Group
Value
95% CI
Short Implant
17
Long Implant
15
12 months
Group
Value
95% CI
Short Implant
17
Long Implant
15
24 months
Group
Value
95% CI
Short Implant
15
Long Implant
15
Number of Sites With Bleeding on ProbingSecondary· 5 month post-op, 12 month post-op, and 24 month post-op visits
The number of sites with bleeding on probing will be compared between the two groups. Bleeding on probing of the implant site will be measured with a periodontal probe at the 5 month post-op, 12 month post-op, and 24 month post-op visits.
The probing pocket depths will be compared between the two groups. Probing depths of the implant site will be measured with a periodontal probe at the 5 month post-op, 12 month post-op, and 24 month post-op visits.
5 months (loading)
Group
Value
95% CI
Short Implant
2.84
± 0.15
Long Implant
2.94
± .15
12 months
Group
Value
95% CI
Short Implant
3.32
± 0.14
Long Implant
3.27
± .15
24 months
Group
Value
95% CI
Short Implant
3.79
± 0.16
Long Implant
3.72
± .16
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data was collected during each subject's entire participation in the study (approximately 2 years).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to evaluate the survival rate of 5 mm short implants compared to longer implants (10 mm) placed in sinus-grafted sites.
Primary aim: Compare bone loss between the two groups Secondary aim: Compare surgical time and patient-reported outcomes (satisfaction and post-operative pain)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06653868 — Grafting of the Peri-implant Bony Defects Around Immediate Implants Using Xenogenic Versus Alloplastic Sticky Grafts: Ra
· NA
· recruiting
NCT06933030 — Assessment of Customized 3D Zirconium Versus Titanium Mesh for Anterior Maxillary Ridge Augmentation With Delayed Implan
· NA
· active not recruiting
NCT06559605 — Evaluation of Bone Gain Using Customized 3D Zirconia Barrier Versus Titanium Mesh
· NA
· recruiting
NCT05602493 — A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Al
· Phase 3
· active not recruiting
NCT05610748 — Implant-supported Rehabilitation With SPAL Technique or Soft Tissue Augmentation
· Phase 4
· active not recruiting
Other University of Michigan trials
Trials by the same sponsor.
NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation
· NA
· not yet recruiting
NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)
· NA
· not yet recruiting
NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness
· NA
· not yet recruiting
NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health
· NA
· not yet recruiting
NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults
· NA
· recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan
Last refreshed: 6 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04144322.